Laboratory members



Research interests

Anna Wu

Akinyemi O. Oni-Orisan, PharmD, PhD

Principal Investigator

[email protected]

X Profile (formerly Twitter): @Akinyemi_OO

Introduction: Brains and Braggadocio (audio, 50 minutes).

Pronouns: he/him/his

Clinical validation of pharmacogenetic associations for cardiovascular therapies.


Michael Douglas, MS

Program Manager

[email protected]

X Profile (formerly Twitter): @MDouglas_MS

Pronouns: he/him/his

Evaluating the equitable implementation of new technologies in precision medicine for cardiovascular disease, cancer, and pharmacogenomics.

Boxuan "Jeffrey" Fan, BS

Post-baccalaureate Researcher

[email protected]

Pronouns: he/him/his

Exploring the application of data science, statistics, and computer science in the biomedical field, currently with an emphasis on pharmacogenomics.


Tanushree Haldar, PhD

Data Scientist

[email protected]

Pronouns: she/her/hers

Implementing statistical methods in both local and cloud computing platforms to analyze biomedical data with special emphasis on pharmacogenomics and genetic epidemiology.


Mark Kvale, PhD


[email protected]

Pronouns: he/him/his

Using statistical genetics and machine learning techniques to analyze data, to infer results in large-scale genetic and genomic experiments, and to develop novel approaches to analysis.


James Najera, MS

PhD Student in Epidemiology and Translational Science

[email protected]

Pronouns: he/him/his

Using population genetics, gene-environment interaction, and integration of omics for big data analytics. As a doctoral student, I aim to address health disparities among underrepresented communities in the field of genomic research.

Oluwaseun "Seun" Odusan, BS

Post-baccalaureate Researcher

[email protected]

Pronouns: he/him/they/them

Strong interest in researching disparities in cardiovascular disease within underrepresented groups.

Neven Sarhan, PhD

Postdoctoral Fellow

email pending

Pronouns: she/her/hers

Applying statistical analysis to identify pharmacogenetic relationships related to cardiovascular therapies.

Nanase Toda, BS

PhD student in Pharmaceutical Sciences and Pharmacogenomics

[email protected]

Pronouns: she/her/hers

Developing and evaluating precision medicine tools to optimize the risk and benefit for therapies.

Imani Warren, BS

PhD student in Pharmaceutical Sciences and Pharmacogenomics

[email protected]

Pronouns: she/her/hers

Evaluation of genetic ancestry versus social factors on race/ethnicity-based drug efficacy, safety, and drug response differences.


Photo Name, Role, Years   Project Now

Joseph Harmon, BS

Research Associate


Undergraduate Research Assistant


  PlacEbo-controlled, Randomized, patient-Selected Outcomes N-of-1 triaL (PERSONAL-pilot): alpha-blockers for lower urinary tract symptoms PhD student, Scripps Research. 

Janille Miranda, PharmD

Intensive Research Project PharmD student


  Candidate genetic variants of statin-induced myotoxicity. PGY-1 ambulatory care pharmacy resident, Stanford University.

Mari Cayabyab, PharmD

Clinical Pharmacology and Therapeutics (CPT) postdoctoral fellow



Coronary heart disease polygenic risk score and secondary prevention of myocardial infarction.

Abstract/Award: Cayabyab et al. Clin Pharmacol Ther. 2022;111: S63. Jason Morrow Trainee Award winner (2nd-best trainee abstract at the conference).

Clinical pharmacy specialist – pharmacogenomics, University of Pennsylvania.

Siem Tsegay

Summer Student Research Program (SSRP) undergraduate student


  Pilot study to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of tamsulosin deprescribing. Undergraduate student, Macalester College.

Brian Lu, PharmD

Pharmacogenomics Discovery Project PharmD student



Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin.

Publication: Lu et al. Clin Pharmacol Ther. 2021 Sep;110(3):733-740. PMID: 34114646.

Clinical pharmacist, Stanford Health Care Tri-Valley

Laura Sun, PharmD

Pharmacogenomics Discovery Project PharmD student


  Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin Clinical pharmacist, Winship Emory Midtown

Adeya Wyatt, BS

Summer Research Project undergraduate student


  The impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on inflammatory biomarkers. PhD student, Columbia University, Biomedical Engineering